XRCC1基因多态性与分化型甲状腺癌风险的相关性

Exploration of the correlation between XRCC1 gene polymorphism and differentiated thyroid cancer

目的探究XRCC1基因多态性与分化型甲状腺癌患病风险的相关性。方法选取138例分化型甲状腺癌患者作为观察组,选取同一时间健康查体正常者146例作为对照组,通过聚合酶链式反应-限制性片段长度多态性(RFLP)方法对其XRCC1基因136以及268位点进行检测并探究不同基因型与分化型甲状腺癌发病的关系。结果观察组XRCC1基因136位呈现基因多态性,其中AA、AG所占比例显著高于GG所占比例(P均<0.05);且136位氨基酸构成显示,观察组Arg/Arg所占比例明显低于对照组(P<0.05),Arg/Lys以及Lys/Lys所占比例均明显高于对照组(P均<0.05);分化型甲状腺癌患者中,基因型为Arg/Arg者所占比例明显低于基因型为Arg/Lys及Lys/Lys者(P均<0.05);2组XRCC1基因268位GG、GC、CC所占比例及Arg/Arg、Arg/Thr以及Thr/Thr所占比例比较差异均无统计学意义(P均>0.05)。结论XRCC1基因136位点基因多态性可以显著增加罹患分化型甲状腺癌风险,但是268位点基因多态性与罹患分化型甲状腺癌之间并无相关性。

Objective It is to investigate the correlation of XRCC1 gene polymorphism with the risk of differentiated thyroid cancer. Methods 138 cases of differentiated thyroid cancer patients were selected as the observation group,and meanwhile 146 healthy people were selected at the same time as control group,the method of polymerase chain reaction restriction fragment length polymorphism（ RFLP） was adopted to detect the 136 and 268 locus in XRCC1 gene,and the relationship between them were analyzed. Results In the observation group,the XRCC1 gene 136 locus was presented as a genetic polymorphism,and the proportion of AG and AA was significantly higher than that of GG（ all P 〈0. 05）; and the amino acid composition of 136 locus showed,the proportion of Arg / Arg in the observation group was significantly lower than that in the control group（ P 〈0. 05）,the proportion of Arg / Lys and Lys / Lys were significantly higher than that in the control group（ all P 〈0. 05）; in the differentiated thyroid cancer patients,the proportion of genotype Arg / Arg were significantly lower than that of Arg / Lys and Lys / Lys（ all P 〈0. 05）; there was no significant difference in the proportion of XRCC1 gene 268 locus GG,GC,CC,Thr / Thr,Arg / Thr and Arg / Arg between the 2 groups（ all P 〉0. 05）. Conclusion The polymorphism of XRCC1 gene 138 locus can significantly increase the risk of differentiated thyroid cancer,but there is no correlation between the 268 polymorphisms and the risk of differentiated thyroid cancer.